abstract |
The invention relates to liquid formulations of human interferon- beta . The inventive formulations are characterised in that they have a buffer with a pH value in the slightly acidic to neutral range between 5 and 8, preferably between 5.5 and 8, and in that the interferon- beta is highly stable in solution, the molecular integrity being preserved. |